Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia.

Literature DB >> 12124170

Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia.

Abstract

Activating mutations in the FLT3 receptor tyrosine kinase occur in 30% of patients with acute myeloid leukemia. Small molecule FLT3 kinase inhibitors show selective antitumor activity in preclinical models. Clinical studies are underway.

Entities: Disease Gene Species

Mesh：

Substances：

Year: 2002 PMID： 12124170 DOI： 10.1016/s1535-6108(02)00080-6

Source DB: PubMed Journal: Cancer Cell ISSN： 1535-6108 Impact factor: 31.743

Keyword Cloud
Cited

16 in total

Review 1. Acute myeloid leukemia: advancing clinical trials and promising therapeutics.

Authors: Naval Daver; Jorge Cortes; Hagop Kantarjian; Farhad Ravandi
Journal: Expert Rev Hematol Date: 2016-03-17 Impact factor: 2.929

2. Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.

Authors: Farhad Ravandi; Jorge E Cortes; Daniel Jones; Stefan Faderl; Guillermo Garcia-Manero; Marina Y Konopleva; Susan O'Brien; Zeev Estrov; Gautam Borthakur; Deborah Thomas; Sherry R Pierce; Mark Brandt; Anna Byrd; B Nebiyou Bekele; Keith Pratz; Rajyalakshmi Luthra; Mark Levis; Michael Andreeff; Hagop M Kantarjian
Journal: J Clin Oncol Date: 2010-03-08 Impact factor: 44.544

3. Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.

Authors: Feng-Chun Yang; Shi Chen; Travis Clegg; Xiaohong Li; Trent Morgan; Selina A Estwick; Jin Yuan; Waleed Khalaf; Sarah Burgin; Jeff Travers; Luis F Parada; David A Ingram; D Wade Clapp
Journal: Hum Mol Genet Date: 2006-07-11 Impact factor: 6.150

4. Internal tandem duplications of the FLT3 gene are present in leukemia stem cells.

Authors: Mark Levis; Kathleen M Murphy; Rosalyn Pham; Kyu-Tae Kim; Adam Stine; Li Li; Ian McNiece; B Douglas Smith; Donald Small
Journal: Blood Date: 2005-03-29 Impact factor: 22.113

5. Tyrosine phosphorylation regulates maturation of receptor tyrosine kinases.

Authors: Dirk-E Schmidt-Arras; Annette Böhmer; Boyka Markova; Chunaram Choudhary; Hubert Serve; Frank-D Böhmer
Journal: Mol Cell Biol Date: 2005-05 Impact factor: 4.272

6. Exons 19 and 21 of epidermal growth factor receptor are highly conserved in squamous cell cancer of the head and neck.

Authors: Matthew Carlson; Beverly Wuertz; Jizhen Lin; Randy Taylor; Frank Ondrey
Journal: Int J Otolaryngol Date: 2010-01-05

Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia.

Review 1. Acute myeloid leukemia: advancing clinical trials and promising therapeutics.

2. Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.

3. Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.

4. Internal tandem duplications of the FLT3 gene are present in leukemia stem cells.

5. Tyrosine phosphorylation regulates maturation of receptor tyrosine kinases.

6. Exons 19 and 21 of epidermal growth factor receptor are highly conserved in squamous cell cancer of the head and neck.

7. Gene mutations and molecularly targeted therapies in acute myeloid leukemia.

Review 8. Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia.

Review 9. Flt3 in acute myelogenous leukemia: biology, prognosis, and therapeutic implications.

10. Understanding and Targeting the Eukaryotic Translation Initiation Factor eIF4E in Head and Neck Cancer.